抑制CCL20治疗结性脊髓炎炎炎症的炎症
Eun Jeong Won1, Hui-Ju Kim2, Yu Jeong Lee2
1Department of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Rheumatology (Oxford, England)
|June 6, 2023
概括
向C-C动机化学基因配体20 (CCL20) 显示出治疗结性脊髓炎 (AS) 的前景. 在小鼠模型中,抑制CCL20降低了Th17细胞迁移和关节炎症,这表明了新的治疗策略.
科学领域:
- 免疫学 免疫学 免疫学
- 类风湿病学 类风湿病学
- 分子生物学分子生物学
背景情况:
- Th17细胞与结性脊髓炎 (AS) 病变发生有关.
- 通过C-C基因基因受体6 (CCR6),CC-C基因基因受体20 (CCL20) 促进Th17细胞通过CC基因受体6 (CCR6) 向炎症部位迁移.
研究的目的:
- 调查AS中CCL20抑制的治疗潜力.
- 评估CCL20在Th17细胞迁移和AS关节炎症中的作用.
主要方法:
- 从AS患者和健康对照中收集的外周血液单核细胞 (PBMC) 和突液单核细胞 (SFMC).
- 使用流细胞计,ELISA,跨井迁移测定和SKG小鼠模型来评估Th17细胞,CCL20水平,细胞迁移和体内炎症.
- 分析了与AS疾病活动相关的细胞因子产生和CCL20表达.
主要成果:
- 与PBMC相比,在AS SFMC中观察到Th17细胞和CCL20表达细胞的增加.
- 在AS突流体 (SF) 中,CCL20水平明显高于骨关节炎 (OA) SF.
- 在SKG小鼠模型中,CCL20抑制减少了Th17细胞迁移,并显著降低了关节炎症.
结论:
- CCL20在AS的发病过程中起着至关重要的作用.
- 准CCL20代表了AS治疗的有前途的治疗策略.
相关概念视频
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
177
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
177
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
204
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
204
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
161
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
161
01:29Drugs for Treatment of Ulcerative Colitis in IBD
179
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
179
01:19Antiasthma Drugs: Leukotriene Modifiers
375
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
375
01:29Inflammatory Bowel Disease IV: Pharmacological Management
159
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
159